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Summary: 
PBMC cultures from asthma patients synthesised high levels of IL-17A compared to non-asthmatic 
controls, most significantly in steroid refractory patients. Glucocorticoids could enhance IL-17A, but 
1,25(OH)2D3 inhibited this response in a glucocorticoid-independent manner. 
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Abstract 
Background: Th17 cells are proposed to play a role in the pathology of asthma, including steroid 
resistant disease. We previously identified a steroid-enhancing function of vitamin D in steroid 
resistant asthma, in restoring the impaired response to steroids for production of the anti-inflammatory 
cytokine IL-10.  
Objective: To investigate the production of the Th17-associated cytokines IL-17A and IL-22 in 
culture in moderate-severe asthma patients defined on the basis of their clinical response to steroids, 
and the susceptibility of this response to inhibition by steroids and the active form of vitamin D, 
1,25(OH)2D3. 
Methods: PBMC were stimulated in culture with or without dexamethasone and 1,25(OH)2D3. 
Cytometric bead array, ELISA and intracellular cytokine staining were used to assess cytokine 
production. The role of CD39 in inhibition of the Th17 response was studied by qRT-PCR, flow 
cytometry and addition of the antagonist, POM-1, to culture. 
Results: Asthma patients synthesised much higher levels of IL-17A and IL-22 than non-asthmatic 
control subjects, with steroid resistant asthmatics expressing the highest levels of IL-17A.  
Glucocorticoids did not inhibit IL-17A cytokine expression in patients, and enhanced production in 
cultures from control subjects. Treatment with 1,25(OH)2D3, with or without dexamethasone, 
significantly reduced both IL-17A and IL-22. An antagonist of the ectonucleotidase CD39 reversed 
1,25(OH)2D3 mediated inhibition of the IL-17A response.  
Conclusion: Severe asthmatics exhibit elevated levels of Th17 cytokines, which is not inhibited by 
steroids. 1,25(OH)2D3 inhibits Th17 cytokine production in all patients studied, irrespective of their 
clinical responsiveness to steroids, identifying novel steroid-enhancing properties of vitamin D in 
asthma. 
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Introduction 
Asthma is broadly defined as bronchial hyperresponsiveness with reversible expiratory airflow 
limitation. Historically asthma has been described as having an underlying Th2-mediated 
inflammatory profile, however there is increasing evidence for heterogeneity in asthma phenotypes 
with a significant proportion of asthma patients demonstrating a low or non-Th2 mediated phenotype 
that appears less sensitive to control by glucocorticoids (1, 2). Although glucocorticoids are currently 
the most effective treatment for asthma, steroid resistant (SR) asthma is a significant clinical problem. 
These patients generally require prolonged systemic treatment, their asthma is less stable and more 
difficult to control and they are subject to higher morbidity and mortality (3-6). The precise cause or 
causes of SR asthma are unknown, but several mechanisms have been proposed to account for it 
(reviewed in (7-10)), including genetic susceptibility, defects in glucocorticoid receptor (GR) binding, 
increased expression of the functionally inactive GR-, activation of transcription factors such as AP-
1 (activator protein 1) or decreased synthesis of immunoregulatory cytokines like IL-10. Although it 
is difficult to investigate SR asthma in patients with milder disease, because its definition is based on 
improvement in originally abnormal lung function, it is reasonable to suppose that SR asthma is likely 
to be associated with severe, difficult to control disease. 
 
Th17 cells are critical for defence against bacterial and fungal infections (11). Mouse models 
demonstrate that animals deficient in IL-17A or IL-17RA are highly susceptible to infection with 
mucosal pathogens such as Klebsiella pneumoniae, and Candida albicans (12, 13). IL-17A-mediated 
activation of the innate immune system and neutrophil influx can be protective against infection but 
can also lead to damage of the surrounding tissues associated with immune pathology (14, 15). 
 
A body of circumstantial evidence consistent with the hypothesis that IL-17A exacerbates asthma 
and/or reduces patients’ responsiveness to therapy already exists. Thus IL-17A expression in sputum 
or bronchial mucosal biopsies has been correlated with bronchial hyperresponsiveness (16), 
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granulocyte infiltration (17) and production of fibrogenic mediators by bronchial fibroblasts (18). 
Furthermore, elevation of serum IL-17A concentrations appears to be both a marker (19) and an 
independent risk factor for severe asthma (16-18, 20, 21).  Involvement of Th17 cells in severe steroid 
resistant asthma is proposed from murine and human studies (22, 23). In addition to IL-17A, IL-22 is 
commonly produced by Th17 cells. In various animal models of disease IL-22 can elicit damaging or 
protective responses possibly dependent on the location, cellular sources, cytokine milieu and timing 
of its expression (24-26).  
 
There is great interest in the therapeutic potential of vitamin D to regulate the severity of asthma and 
to reduce the amount of anti-inflammatory medication required for disease control. Several studies 
have pointed out striking links in populations between vitamin D deficiency and asthma severity or 
requirements for anti-inflammatory medication (27-30). In previous studies investigating the 
immunological basis of this relationship, we have shown that 1 α,25-dihydroxyvitamin D3 
(1,25(OH)2D3) exerts immunomodulatory effects on T cells from patients with SR asthma patients, 
enhancing the impaired steroid-induced IL-10 response in these individuals (31), while others  have 
highlighted the capacity of this molecule to inhibit Th17 responses (32-35). 
 
Building on these studies we hypothesised that 1,25(OH)2D3 inhibits elevated IL-17A production by 
blood Th17 cells from severe asthmatics independently of glucorticoids in vitro and independently of 
their clinical responsiveness to glucorticoid therapy in vivo. To address the hypothesis we studied the 
effects of 1,25(OH)2D3 and the glucocorticoid dexamethasone on the production of IL-17A and its 
common co-product IL-22, by peripheral blood CD4+ T cells from a cohort of severe asthmatics, 
carefully characterised for their clinical glucocorticoid responsiveness, and non-asthmatic controls. 
Finally, in an attempt to elucidate possible mechanisms of the effect of 1,25(OH)2D3 in altering IL-
17A production, we measured its effects on the expression of the ectonucleotidase CD39, elevated 
expression of which has previously been reported to be associated with inhibition of IL-17A 
production in autoimmune disease (36). We hypothesised that dexamethasone, but not 1,25(OH)2D3 
reduces CD39 expression on blood T cells and that inhibition of its ectonucleotidase activity abolishes 
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any effects of 1,25(OH)2D3 on IL-17A expression. 
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Materials and Methods 
Subjects 
Healthy adults (study approved by the local research ethics committee, 09/H0804/77) and asthma 
patients (08/H0804/84) were recruited. All healthy controls and patients gave written informed 
consent. Asthma patients had moderate to severe asthma for at least 6 months on therapy step 3 or 4 
of the British Thoracic Society (BTS) guidelines on management of asthma, diagnosed by a specialist 
physician. The average inhaled corticosteroid dose in beclomethasone diproprionate equivalent was 
1177mcg for SR patients and 1180mcg for SS patients. All patients had a pre-bronchodilator FEV1 of 
< 80% predicted, documented airway variability of > 12% following 400mcg of short-acting 
bronchodilator and had undergone detailed assessment to exclude a diagnosis other than asthma and 
co-morbidities affecting asthma control. Patients were not on oral corticosteroids for 4 weeks prior to 
the study. Steroid sensitivity was defined by an increase in FEV1 > 10% from baseline following a 2 
week course of Prednisolone of 40mg/1.73m2 body surface area. Steroid resistance was defined by a 
<10% increase in FEV1 from baseline following a 2 week course of Prednisolone of 40mg/1.73m2 
body surface area. Compliance with Prednisolone during the study was assessed with Cortisol serum 
levels pre- and post-steroids. Patients on immunotherapy, smokers or patients who suffered from a 
respiratory tract infection or asthma exacerbation during or 4 weeks prior to enrolling for the study 
were excluded. 18 steroid resistant (SR) and 10 steroid sensitive (SS) patients were assessed with a 
mean age of 54 (SR) and 50 years (SS). Mean pre-bronchodilator FEV1 before and after a course of 
oral corticosteroids was 1.99L (64.56%) and 1.96L (64.05%) in the SR patients and 1.72 (57.1%) and 
2.19L (73.2%) in the SS patients (post steroid FEV1 SR vs SS p<0.001, ANCOVA), 10 healthy 
controls were assessed for comparison, mean age 41.  
 
Cell isolation and Culture 
Human PBMC were isolated as previously described (31). Briefly, CD8-depleted PBMCs were 
obtained by negative selection using CD8+ Dynalbeads (Invitrogen, Paisley, U.K.). CD4+ T cells 
were purified by positive selection using Dynalbeads. Cells (1x106 cells/ml) were cultured in RPMI 
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(containing 10% FCS, 2mM L-glutamine and 50 µg/ml gentamycin), and stimulated with plate-
bound anti-CD3 (1g/ml; OKT-3) plus 50U/ml recombinant hIL-2 (Eurocetus, Harefield U.K.), in the 
presence or absence of Dexamethasone (Sigma-Aldrich, Gillingham, U.K.) and 1 α,25-
dihydroxyvitamin D3 (1,25(OH)2D3; BIOMOL Research Labs, Exeter U.K.) at the indicated 
concentrations in a 24-well plate, for 7-days.  There was no significant difference between viability 
between the different conditions (data not shown). Where indicated, cells were re-cultured at the same 
density of 1x106/ml after 7 days with plate-bound anti-CD3 and IL-2 alone in a 48-well plate and 
supernatants were harvested at 48 hours for cytokine analysis. 
 
Flow Cytometry 
The following antibodies were used for cell surface phenotyping: CD3 (SK7; BD Biosciences, 
Oxford, U.K.), and CD39 (ebioA1; eBiosciences, Hatfield, U.K.). For ex vivo staining, red blood cells 
were lysed using Facs Lysing solution (working dilution 1:10; BD Biosciences), then were further 
stained for intranuclear Foxp3 (PCH101; ebiosciences) using the Foxp3 staining kit as per the 
manufacturer’s instructions (ebiosciences). 
For intracellular cytokine staining on day 7, cells were restimulated for 4 hours with 5 ng/ml phorbol 
12-myristate 13-acetate (PMA) and 500 ng/ml ionomycin, with 2 µM monensin (Sigma-Aldrich) 
added for the final 2 hours. Cells were washed, fixed, and permeabilised using Cytofix/Cytoperm kit 
(BD Biosciences) and were stained with fluorescently labeled monoclonal antibodies to IL-22 and IL-
17A (22URTI and eBio64CAP17; ebiosciences).  Dead cells (7-aminoactinomycin D [7-AAD] 
positive; Sigma-Aldrich) were gated out. Analysis was performed using a FACSCalibur flow 
cytometer (BD Biosciences). 
 
qRT-PCR 
RNA was extracted from cell pellets using the RNeasy Mini kit (Qiagen, Crawley U.K.) according to 
the manufacturer’s instructions. The RNA was quantified using Nanodrop ND-1000 
spectrophotometer (ThermoScientific, Wilmington U.S.A.) 250ng of RNA was reverse transcribed 
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into cDNA. qRT-PCR was performed in triplicate using an Applied Biosystems 7900 HT system and 
FAM labelled Assay-on-Demand reagent sets for CD39 (Hs00969559_m1). qRT-PCR reactions were 
multiplexed using VIC labelled 18S primers and probes (Hs99999901_s1) as an endogenous control 
and analyzed using SDS software version 2.1 (Applied Biosystems, Foster City U.S.A.), according to 
the 2-(∆∆Ct) method. 
 
Cytokine Analysis 
IL-22 was measured using ELISA and matched antibody pairs (BD Biosciences). The lower limit of 
detection for IL-22 was 100 pg/ml. IL-17A, IL-10, IFNγ and IL-5 were measured by Cytometric Bead 
Array (BD Biosciences) according to the manufacturers protocol, the lower limit of detection was 1.5 
pg/ml.  
 
Statistics 
Data are presented as the mean ± standard error of the mean (SEM), unless indicated. Data were 
assessed for equivalence to a Gaussian distribution and equality variance after which the appropriate 
parametric or non-parametric test was performed (see individual figure legends). Differences were 
considered significant at the 95% confidence level. 
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Results 
Comparison of IL-17A and IL-22 production by PBMCs in culture from Steroid Sensitive (SS) 
and Refractory (SR) asthma patients 
Details of the two cohorts of moderate to severe asthma patients, defined as SS or SR on the basis of 
changes in their lung function following a 2-week course of oral prednisolone, and of healthy non-
asthmatic control subjects studied, are provided in Materials and Methods. Notably these two patient 
groups exhibited comparable disease severity based on impairment of lung function, and were taking 
comparable doses of inhaled corticosteroids (total dosages based on beclomethasone dipropionate 
(BDP) equivalence).  
 
PBMCs from the asthma patients were evaluated for their capacity to synthesise the Th17-associated 
cytokines IL-17A and IL-22 in culture, and comparisons made with control subjects. PBMCs depleted 
of CD8+ T cells were stimulated in vitro with anti-CD3 and IL-2 for seven days and then stained for 
intracellular cytokine expression. Significantly greater percentages of IL-17A+ and IL-22+ expressing 
cells were observed in cultures from asthma patients, as compared to healthy control subjects (Figure 
1A & B). When patients were subdivided based on clinical responsiveness to glucocorticoids only SR 
patients showed a significant difference in IL-17A immunoreactivity (SR p=0.003; SS p=0.142) and 
IL-22 immunoreactivity (SR p=0.037; SS p=0.701), compared to control subjects (Figure 1B). Cells 
co-expressing IL-17A and IL-22, are proposed to represent the most pathogenic population, and were 
significantly increased in all asthmatics and SR asthmatics compared to healthy control subjects (all 
asthmatics p=0.029; SR p=0.009).  At seven days cells were also harvested and re-cultured at equal 
cell densities for 48h with anti-CD3 and IL-2 alone. Culture supernatants from asthma patients 
contained significantly higher quantities of secreted IL-17A and IL-22 as compared to healthy 
controls (Figure 1C). Production of IL-17A and IL-22 was significantly increased in SR compared to 
controls (IL-17A: p=0.009; IL-22: p=0.036). Supernatants from SR had significantly more IL-17A as 
compared to SS (p=0.016), whereas culture supernatants from SS and SR patients contained 
comparable levels of IL-22 (Supplementary Figure 1A). 
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Glucocorticoids fail to inhibit IL-17A and IL-22 synthesis in culture 
The capacity of glucocorticoids to alter production of IL-17A and IL-22 was next examined.  
Addition of 10-7M dexamethasone to cultures from healthy controls significantly increased the mean 
percentage of cells expressing IL-17A, but did not alter the low percentage of cells expressing IL-22 
(Figure 2A).  IL-17A and IL-22 secretion were increased in a concentration-dependent manner by 
dexamethasone in cultures from healthy donors (Figures 2B, 2C). IL-2 is present in the stimulation 
cultures, and addition of IL-2 plus IL-4 has previously been described to promote steroid insensitivity 
in culture (37). The effects of dexamethasone were therefore assessed in the presence or absence of 
anti-CD3 and/or IL-2 on IL-17A and a range of additional cytokines (Supplementary Figure 2). 
Notably, IL-17A (and IL-10) enhancement by dexamethasone only occurred when the combination of 
anti-CD3 and IL-2 was present. Dexamethasone inhibited the production of IFNγ, IL-13, and IL-5 
although the inhibition of IFN in particular was less marked when anti CD3 plus IL-2, as compared 
to anti CD3 or IL-2 alone, was present in these cultures.  
The effects of dexamethasone in asthmatic patient cultures was less marked, where notably there was 
a more than sevenfold higher basal level of IL-17A synthesis compared to non-asthmatic cultures 
(Figure 2B). A trend towards increased IL-17A secretion (p=0.102; Fig 2B),  and a significant 
increase in the frequency of IL-17A positive cells in patient cultures containing dexamethasone 10-7M 
was observed (Figure 3A). An effect observed in both SS and SR subgroups was partial inhibition by 
dexamethasone of IL-22 secretion (Figure 2C and Supplementary Figure 1). 
 
1 α,25-dihydroxyvitamin D inhibits IL-17A and IL-22 expression 
The capacity of 1,25(OH)2D3 to inhibit IL-17A production alone and in combination with 
dexamethasone was next investigated in cultures from asthmatic patients. 1,25(OH)2D3 significantly 
decreased the mean percentages of cells immunoreactive for IL-17A or IL-22 in culture (Figure 3A, 
3B). Although dexamethasone failed to reduce IL-22 or IL-17A immunoreactivity compared to 
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control cultures, the combination of dexamethasone and 1,25(OH)2D3 led to a marked reduction in 
the frequency of cytokine positive cells that was not significantly different from cultures with 
1,25(OH)2D3 alone (Figure 3A, 3B). Protein expression in culture supernatants following 
1,25(OH)2D3 treatment alone, or in combination with dexamethasone, demonstrated a comparable 
trend with no significant difference in the mean concentration of IL-17A or IL-22 between cultures 
containing 1,25(OH)2D3, or 1,25(OH)2D3 plus dexamethasone (Figure 3B, 3C). The effects of 
1,25(OH)2D3 on IL-17A and IL-22 synthesis were comparable in the SS and SR asthmatics 
(Supplementary Figure 1B). The reduction of IL-17A production by 1,25(OH)2D3 is unlikely to be 
explained by inhibition of proliferation (Supplementary Figure 3) or decreased viability (data not 
shown) as 1,25(OH)2D3 at the concentration used did not inhibit either as we recently reported (38). 
These data highlight the capacity of 1,25(OH)2D3 to counteract any detrimental or lack of effect of 
dexamethasone on Th17-associated cytokine synthesis in cell cultures from asthma patients. 
1,25(OH)2D3 effectively inhibited IL-17A production in cultures from healthy control subjects (data 
not shown), as previously reported by others (33-35). 
 
1,25(OH)2D3 enhances expression of CD39+ T cells, a potential mechanism for IL-17A 
inhibition 
Expression of the ectonucleotidase CD39 by Foxp3+ T regulatory cells (Treg) has previously been 
reported to be associated with inhibition of IL-17A production (36, 39, 40). Analysis of ex vivo 
expression of CD39 demonstrated a significantly higher frequency of CD3+CD39+ T cells  in the 
peripheral blood of healthy donors as compared to severe asthmatics (p=0.003). CD39 can be 
expressed on both CD4+ memory and Foxp3+ T cells (36, 39), so we further analysed expression on 
Foxp3+ and Foxp3- populations. A significantly higher frequency of CD39 expressing cells was 
detected in both CD3+Foxp3- and CD3+Foxp3+ T cells in the non-asthmatic donors as compared to 
the severe asthmatics (Figure 4A), in contrast to the higher IL-17A synthesis observed in the patients.  
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The impact of 1,25(OH)2D3 and dexamethasone on CD39 expression, was next investigated. CD4+ T 
cells cultured in the presence of 1,25(OH)2D3  demonstrated a significantly increased gene expression 
of CD39 (Figure 4B). When surface expression of CD39 was assessed by flow cytometry there was a 
modest but significant increase in the level of expression of CD39 as determined by Mean 
Fluorescence Intensity (MFI), but there were no differences in the overall frequency of CD39+ T 
cells. In comparison addition of dexamethasone reduced the percentage of CD39+ T cells and MFI 
(Figure 4C and D). To investigate the role of CD39 in 1,25(OH)2D3 inhibition of IL-17A production 
we employed POM-1, a known inhibitor of CD39 ectonucleotidase activity. POM-1 partially 
abrogated the inhibition of IL-17A synthesis effected by 1,25(OH)2D3 in cultured T cells. This effect 
was specific for IL-17A since the production of IL-10 and other Th1 and Th2 cytokines was not 
affected (Figure 4E).
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Discussion 
Our data demonstrate that the production of IL-17A and IL-22 by human peripheral blood CD4+ T 
cells is elevated in severe asthma. Notably, IL-17A, but not IL-22 was approximately 5-fold greater in 
SR as compared to SS asthmatics. Strikingly the glucocorticoid dexamethasone significantly 
enhanced the frequency of IL-17A positive cells in culture in both non-asthmatic control and 
asthmatic subjects, although IL-17A secretion was only significantly increased by dexamethasone in 
control cultures. In contrast the active form of vitamin D reduced both cytokines directly and also 
when dexamethasone was present in culture. Importantly this in vitro effect was equivalent in 
clinically glucocorticoid resistant and sensitive asthma patients, with greater than 80% inhibition of 
the Th17 response in both patient cohorts. The data support a potential role for the ectonucleotidase 
CD39 in 1,25(OH)2D3 mediated inhibition of the IL-17A response. Together our data are consistent 
with the hypothesis that 1,25(OH)2D3, through inhibition of IL-17A, improves disease control in 
asthmatics independently of their glucocorticoid responsiveness. 
 
The present study extends earlier observations showing an association between elevated IL-17A 
production and severe asthma by investigating two asthma patient cohorts with clearly defined clinical 
responsiveness or non-responsiveness to steroids at the time of study, but comparable disease 
severity. While blood T cells from all asthmatics demonstrated elevated IL-17A and IL-22 synthesis, 
the most striking differences from the control group were observed in the SR asthma patients. 
Analysis of cytokine production from SS patients alone demonstrated a non-significant trend for 
enhanced IL-17A and IL-22 production in comparison to healthy control subjects. In comparisons 
between SS versus SR asthmatics, the most notable differences were in the frequency of the levels of 
secreted IL-17A and IL-17A+ IL-22+ double positive cells. Double positive conventional T cells are 
proposed to represent the more pathogenic population with studies showing that IL-22 enhances the 
pro-inflammatory properties of IL-17A (32, 41).  
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Independent studies have suggested that Th17 cytokine production plays a mechanistic role in 
increasing asthma severity and reducing corticosteroid sensitivity (22, 42). Nevertheless, we cannot 
completely exclude from the present data the possibility that elevated IL-17A production is associated 
with inhaled corticosteroid administration. Although dexamethasone increased the frequency of IL-
17A positive cells in both non-asthmatic and asthmatic cultures, the levels secreted were only 
significant in non-asthmatic cultures, although a trend for increase was observed (p=0.102).  A major 
difference between these two subject groups was the baseline level of IL-17A synthesis, which was 
more than 7-fold lower in the non-asthmatic cultures as compared to the asthmatic cultures, and may 
contribute to the capacity to visualise the enhancement by dexamethasone. Furthermore, in a 
retrospective analysis of our data we observed an association between inhaled corticosteroid dosages 
(beclometasone equivalent prior to the trial of oral prednisolone therapy) and the amounts of blood 
PBMC IL-17A released in vitro (Pearson correlation r=0.459; p=0.014), supporting the possibility 
that at least some of the IL-17A produced by PBMCs in asthmatics results from corticosteroid 
exposure.  
 
Our data are also broadly complementary of studies in an animal model demonstrating that IL-17A 
production by PBMCs was not inhibited by dexamethasone in culture, and that airways inflammation 
induced in mice by adoptive transfer of Th17 cells was not inhibited by dexamethasone, in contrast to 
that mediated by the adoptive transfer of Th2 cells (22). IL-17A may contribute to asthma 
pathogenesis through a number of different mechanisms such as induction of neutrophilia and 
stimulation of lung innate and structural cells to secrete proinflammatory cytokines (15, 43, 44). Also 
worthy of note is the association of IL-17A with subepithelial fibrosis, a feature of airway 
remodelling shown in some studies to correlate with asthma severity (45). 
 
IL-17A has been proposed to affect global corticosteroid responsiveness through effects on the 
glucocorticoid receptor (GR). GR-α is ubiquitously expressed and is responsible for the induction and 
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repression of target genes, while GR-ß is expressed at much lower levels and is a dominant negative 
inhibitor of GR-α. Increased expression of GR-ß has been linked with severe asthma in some studies 
(42, 46), and a recent study suggested that IL-17A and IL-17F increase the expression of GR-ß, an 
effect that was more prominent in asthmatics than in healthy controls (23). These data imply a 
complex and potentially detrimental relationship between IL-17A, steroid treatment and 
responsiveness in severe asthma, on which vitamin D may have a positive impact. 
We investigated a possible mechanism for the inhibition of T cell IL-17A synthesis by 1,25(OH)2D3. 
The ectonucleotidase CD39, which is expressed by memory T cells as well as Foxp3+ regulatory T 
cells has previously been reported to inhibit IL-17A synthesis (36, 39, 40). In the present study, 
treatment with 1,25(OH)2D3 increased the mean intensity of CD39 expression by human CD4+ T 
cells, while the CD39 antagonist POM-1 partially abrogated 1,25(OH)2D3 -mediated inhibition of the 
IL-17A production, supporting a mechanistic role for this pathway but not excluding others. In 
contrast, dexamethasone tended to reduce CD39 expression. 
Manipulation of vitamin D status for therapeutic benefit in asthma and other respiratory conditions is 
currently highly topical. This arises in part from studies demonstrating that patients with poorly 
controlled asthma and/or poor responsiveness to corticosteroid have significantly reduced vitamin D, 
at least as assessed by the circulating precursor 25-hydroxyvitamin D3 (27-30, 47). We and others 
have previously demonstrated an association with 25(OH)2D3 status and airways smooth muscle mass 
(27, 28, 48). Bronchial smooth muscle hypertrophy and hyperplasia are prominent features of airway 
remodelling as is subepithelial fibrosis, and IL-17A is a key mediator implicated in lung structural 
changes with pro-fibrotic activity within the bronchial epithelium (45). Understanding the various 
mechanisms by which vitamin D controls respiratory health and steroid responsiveness is central in 
targeting this pathway therapeutically and our results provide support for an additional beneficial 
effect. We believe that evidence of 1,25(OH)2D3 down regulating pro-inflammatory cytokines such as 
IL-17A and IL-22, its capacity to enhance anti-microbial pathways, regulatory T cells and other 
homeostatic mechanisms such as CD200 (49), are all likely to contribute to promoting homeostasis in 
the airway and lung health.   
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Figure 1: Severe asthma patients express higher levels of IL-17A and IL-22 
A-C. Control and asthmatic cultures were assessed for IL-17A and IL-22 production by intracellular 
flow cytometry and antibody capture assay. A, Representative dot plots. B, Cumulative data of 
cytokine positive cells (healthy n=8; SS n=8 and SR n=14) and C, secreted cytokines (Healthy n=10; 
SS n=10 and SR n=14). Analysis by students’ t-test, * p<0.05; ** p<0.001. Open circles SS; closed 
squares SR; and closed triangles healthy controls. 
 
Figure 2: Dexamethasone does not inhibit IL-17A production.  
A, Cumulative data of effects dexamethasone on the frequency of IL-17A and IL-22 positive cells in 
non-asthmatic cultures (Healthy n=8), and B-C, IL-17A and IL-22 secretion in control (left) and 
asthmatic cultures (right) (Healthy n=10; Asthmatic n=28). A, Paired t-test and B-C, one-way 
ANOVA with Tukeys post test. * p<0.05; ** p<0.01; *** p<0.001. Dx, Dexamethasone at 10-xM. 
 
Figure 3: 1,25(OH)2D3 inhibits IL-17A and IL-22 in asthmatic patient cultures.                                                       
A, Representative dot plots, B, Cumulative % cytokine positive cells (n=22) or cytokine secretion 
(n=28). 1,25(OH)2D3 reduced IL-17A and IL-22 in asthmatic cultures with or without 
dexamethasone. Statistical significance by one-way ANOVA with Tukeys post test. ** p<0.01;  *** 
p<0.001 ns = non-significant. Dx, Vx, Dexamethasone and 1,25(OH)2D3 respectively, at 10-xM. 
 
Figure 4: 1,25(OH)2D3 increases CD39 expression by CD4+ T cells. 
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A, The frequency of CD39+ (i) CD3+ T cells (ii) Foxp3+ and Foxp3- T cells in the peripheral blood 
of Healthy donors (n=8) and Severe asthma patients (n=19). B-D, Effects of treatment with 
dexamethasone or 1,25(OH)2D3 in culture on healthy non-asthmatic donors B, Relative CD39 mRNA 
(n=5), C, Representative histograms, and D, Cumulative data CD39 expression (n=6). E, cumulative 
data (n=8) effects POM-1 (10µM; CD39 antagonist) on 1,25(OH)2D3-modulation of IL-17A, IFNγ, 
IL-10 and IL-5, expressed as fold change from No drug condition. B and D one-way ANOVA with 
Tukeys post test, E, Wilcox-matched pairs signed rank test. ** p<0.01; *** p<0.001.  
 
Supplementary Figure 1. 1,25(OH)2D3 inhibits Th17-associated cytokines in SS and SR severe 
asthmatics.                
A, Cumulative data showing higher IL-17A expression in SR, and comparable IL-22 in SS and SR 
cultures (SS n=10; SR n=18). B, Secreted IL-17A and IL-22 from SS (left) and SR (right) cultures 
containing dexamethasone and 1,25(OH)2D3 (SS n=10; SR n=18). A, Unpaired t-test and B, one-way 
ANOVA with Tukeys post test. * p<0.05; ** p<0.01; *** p<0.0001. Dx, Vx Dexamethasone and 
1,25(OH)2D3 respectively, at 10-7M. 
 
Supplementary Figure 2. The effect of IL-2 in culture on Dexamethasone modulation of IL-10, 
IFNγ and  IL-5.                       
A, Secreted IFNγ, IL-10, IL-13, IL-5 and IL-17A under different stimulation conditions in healthy 
controls (n=6). Dx  Dexamethasone, at 10-7M.  
 
Supplementary Figure 3. Dexamethasone but not 1,25(OH)2D3 inhibits PBMC proliferation.            
A, Representative dot plots B, Cumulative data showing proliferation of PBMCs in the presence or 
absence of dexamethasone and 1,25(OH)2D3 in healthy controls (n=4). C, Cumulative data cytokine 
secretion data of  IFNγ, IL-10, and IL-5 secretion in healthy donors (n=8). B, and C, one-way 
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ANOVA with Tukeys post test. * p<0.05; ** p<0.01;. Dx, Vx Dexamethasone and 1,25(OH)2D3 
respectively, at 10-xM. 
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